Nine ETFs sold $22.8 million of Lantheus stock on Monday, against three buyers.
FDA approval for BRAVNETSA puts Lantheus Holdings (LNTH) in focus Lantheus Holdings (LNTH) drew fresh attention after the FDA granted final approval for BRAVNETSA, a radiopharmaceutical considered bioequivalent and therapeutically equivalent to LUTATHERA for adult GEP NET patients. The BRAVNETSA approval lands at a time when Lantheus Holdings has seen short term share price pressure, with the stock down over the past three months. Yet its year to date share price return of 48.27% and 1 year...
Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]
Lantheus Holdings (LNTH) said Monday that Curium resubmitted its pre-merger notification, beginning
Committed debt financing supporting the previously announced acquisition of Lantheus Holdings by Curium includes a senior secured multicurrency revolving credit facility and a $4.25 billion senior secured term loan B facility, according to a regulatory filing. In addition, Curium Midco entered into a separate commitment letter for a $1.125 billion PIK facility. The TLB and revolver will be incurred as additional facilities under Curium BidCo’s existing credit agreement, with JPMorgan as administ
This is the newest page. Registered accounts read further back.